Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

Last updated: July 16, 2025
Sponsor: The Netherlands Cancer Institute
Overall Status: Active - Not Recruiting

Phase

2

Condition

Peritoneal Cancer

Malignant Ascites

Ovarian Cysts

Treatment

Cisplatin 40 mg/l

Cisplatin 100 mg/m2

Clinical Study ID

NCT05406674
N21CCI
  • Ages > 18
  • Female

Study Summary

Cytoreductive surgery (CRS) with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is used in current clinical practice in selected patients with advanced ovarian cancer. Clinical evidence for the benefit of HIPEC in ovarian cancer comes from the pivotal phase 3 OVHIPEC trial. Worldwide, two established strategies exist for dosing of HIPEC protocols, which follow either a body surface area (BSA)-based or a concentration-based approach. Since both strategies result in different exposure to intra-peritoneal chemotherapy, we aim to compare the pharmacokinetics and safety of both strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. signed and written informed consent

  2. age ≥ 18 years

  3. patients eligible for interval cytoreductive surgery

  4. histological proven FIGO stage III primary high grade serous ovarian, fallopiantube, or extra-ovarian cancer

  5. when only cytology is performed to confirm the diagnosis ovarian carcinoma,immunohistochemistry should be performed including keratin 7, keratin 20, p53,PAX8

  6. neo-adjuvant chemotherapy consists of (at least) 3 courses ofcarboplatin/paclitaxel

  7. following 2 cycles of chemotherapy no progression should occur

  8. treated with optimal or complete interval cytoreductive surgery

  9. fit for major surgery, WHO performance status 0-2

  10. adequate bone marrow function (hemoglobin level >5.5 mmol/L; leukocytes >3 x 109/L;platelets >100 x 109 /L)

  11. adequate hepatic function (ALT, AST and bilirubin <2.5 times upper limit of normal)

  12. adequate renal function (creatinine clearance ≥ 60 ml/min using Cockcroft-Gaultformula or 24-hour measurement or ml/min/1,73 m2 using MDRD or CKD-EPI)

  13. able to understand the patient information

Exclusion

Exclusion Criteria:

  1. history of previous malignancy treated with chemotherapy

  2. opting for fertility-sparing surgery

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Cisplatin 40 mg/l
Phase: 2
Study Start date:
June 15, 2022
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Antoni van Leeuwenhoek (NKI-AVL)

    Amsterdam, 1066 CX
    Netherlands

    Site Not Available

  • UMCU

    Utrecht,
    Netherlands

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.